Check out our press release hub, powered by Business Wire. It's a one stop shop for industry announcements to help you stay on top of the latest technology and investment trends. Get the scoop here.
Development of Cytox’s novel blood-based mTOR assay highlighted at Copenhagen, DK meeting
MANCHESTER, England–(BUSINESS WIRE)–July 14, 2014–
Cytox, a leading developer of assays for risk assessment and prediction of dementia, announced the timing of a presentation discussing the development of a novel proprietary blood-based assay for the assessment of risk of cognitive decline.
The talk, entitled “The evaluation of mTOR pathway dysregulation as a novel blood-based phenotypic risk biomarker for the assessment of Alzheimer’s Disease and dementia” will be given on Thursday 17 July, between 08.30 and 10.00am, during the AAIC Symposia and Featured Research Sessions at the Bella Centre, A/S Convention Center, Copenhagen, by Professor Harald Hampel of Université Pierre et Marie Curie (Sorbonne), Paris, France.
More information about the event and Professor Hampel’s presentation can be found on the AAIC Conference website at http://bit.ly/1sGQyPh
The presentation refers to two on-going clinical studies in which blood samples are being collected from patients in Europe and in the United States. One study will examine mTOR dysregulation in well-characterized patients who have been diagnosed with probable Alzheimer’s Disease, Fronto-temporal Lobe Dementia (FTLD) or Dementia with Lewy bodies (DLB) against cognitively normal control groups.
A second study will evaluate the performance of the assay platform in patients with mild cognitive impairment (MCI) assessing the relationship between the assay output (mTOR dysregulation) and the presence or absence of amyloid plaques in the brain, a pathological hallmark of Alzheimer’s Disease, using Positron Emission Tomography (PET) imaging.
About Cytox Limited
Cytox Limited is a UK company researching into the role of mTOR pathway dysfunction and the associated development of prognostic tests for cognitive decline and risk of developing AD or other dementias. Cytox has exclusive rights to build on the discoveries made by the company’s scientific founder, Dr. Zsuzsanna Nagy of cell cycle-related biomarkers associated with the risk of developing dementia. The company is developing her work and assessing its significance in trials and will be looking to work with pharmaceutical partners to develop our understanding of the technology and its role in drug development.
For more about the mTOR pathway and its potential role in early identification of risk of Dementia and Alzheimer’s disease, follow this link: www.cytoxgroup.com/information-for-editors
Richard Pither, CEO,
+44 (1865) 338018
VentureBeat is studying mobile marketing automation
, and we’ll share the data.